[go: up one dir, main page]

WO2021234435A1 - Treatment of lung diseases - Google Patents

Treatment of lung diseases Download PDF

Info

Publication number
WO2021234435A1
WO2021234435A1 PCT/IB2020/054826 IB2020054826W WO2021234435A1 WO 2021234435 A1 WO2021234435 A1 WO 2021234435A1 IB 2020054826 W IB2020054826 W IB 2020054826W WO 2021234435 A1 WO2021234435 A1 WO 2021234435A1
Authority
WO
WIPO (PCT)
Prior art keywords
gas
liquid mixture
generator
hydrogen
previous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2020/054826
Other languages
French (fr)
Inventor
Franco Vallana
Toygan SÖNMEZ
Ahmet Ozcan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CID SpA
Original Assignee
CID SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CID SpA filed Critical CID SpA
Priority to PCT/IB2020/054826 priority Critical patent/WO2021234435A1/en
Publication of WO2021234435A1 publication Critical patent/WO2021234435A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
    • A61M16/147—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase the respiratory gas not passing through the liquid container
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
    • A61M16/021—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes operated by electrical means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/1075—Preparation of respiratory gases or vapours by influencing the temperature
    • A61M16/1085—Preparation of respiratory gases or vapours by influencing the temperature after being humidified or mixed with a beneficial agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25B—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES FOR THE PRODUCTION OF COMPOUNDS OR NON-METALS; APPARATUS THEREFOR
    • C25B1/00—Electrolytic production of inorganic compounds or non-metals
    • C25B1/01—Products
    • C25B1/02—Hydrogen or oxygen
    • C25B1/04—Hydrogen or oxygen by electrolysis of water
    • C—CHEMISTRY; METALLURGY
    • C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25B—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES FOR THE PRODUCTION OF COMPOUNDS OR NON-METALS; APPARATUS THEREFOR
    • C25B1/00—Electrolytic production of inorganic compounds or non-metals
    • C25B1/01—Products
    • C25B1/34—Simultaneous production of alkali metal hydroxides and chlorine, oxyacids or salts of chlorine, e.g. by chlor-alkali electrolysis
    • C25B1/46—Simultaneous production of alkali metal hydroxides and chlorine, oxyacids or salts of chlorine, e.g. by chlor-alkali electrolysis in diaphragm cells
    • C—CHEMISTRY; METALLURGY
    • C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25B—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES FOR THE PRODUCTION OF COMPOUNDS OR NON-METALS; APPARATUS THEREFOR
    • C25B15/00—Operating or servicing cells
    • C25B15/02—Process control or regulation
    • C—CHEMISTRY; METALLURGY
    • C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25B—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES FOR THE PRODUCTION OF COMPOUNDS OR NON-METALS; APPARATUS THEREFOR
    • C25B15/00—Operating or servicing cells
    • C25B15/08—Supplying or removing reactants or electrolytes; Regeneration of electrolytes
    • C—CHEMISTRY; METALLURGY
    • C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25B—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES FOR THE PRODUCTION OF COMPOUNDS OR NON-METALS; APPARATUS THEREFOR
    • C25B9/00—Cells or assemblies of cells; Constructional parts of cells; Assemblies of constructional parts, e.g. electrode-diaphragm assemblies; Process-related cell features
    • C25B9/17—Cells comprising dimensionally-stable non-movable electrodes; Assemblies of constructional parts thereof
    • C25B9/19—Cells comprising dimensionally-stable non-movable electrodes; Assemblies of constructional parts thereof with diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/006—Sprayers or atomisers specially adapted for therapeutic purposes operated by applying mechanical pressure to the liquid to be sprayed or atomised
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
    • A61M16/06—Respiratory or anaesthetic masks
    • A61M16/0666—Nasal cannulas or tubing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
    • A61M16/16—Devices to humidify the respiration air
    • A61M16/162—Water-reservoir filling system, e.g. automatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/0078—Special media to be introduced, removed or treated changed by chemical action
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/02—Gases
    • A61M2202/0216—Ozone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0468—Liquids non-physiological
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
    • Y02E60/30—Hydrogen technology
    • Y02E60/36—Hydrogen production from non-carbon containing sources, e.g. by water electrolysis

Definitions

  • the present disclosure relates to treating lung diseases such as lung (respiratory) inflammation diseases.
  • Coronavirus disease 2019 (briefly COVID-19), an infection disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is exemplary of such a disease.
  • SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
  • COVID-19 Diseases such as COVID-19 are primarily spread between people during close contact and may lead to symptoms such as fever, cough, shortness of breath, loss of smell and fatigue.
  • Pneumonia and acute respiratory distress are possible complications which may result in death of the person infected.
  • the disease has been countered mostly via preventive measures such as repeated accurate hand washing, wearing protective face masks, social distancing, (self)isolation of "positive” subjects and/or subjects suspected to be infected.
  • the object of one or more embodiments is to provide a solution that will be able to contribute in countering diseases such as COVID-19 by providing an effective treatment of such devices.
  • the above object may be achieved thanks to a system having the characteristics set for in the claims that follow.
  • One or more embodiments may facilitate treatment of severe diseases caused by infections such as COV1D- 19 infection, dealing directly the inflammation in the lungs which can trigger severe consequences potentially leading to death.
  • COVID- 19 is referred to throughout this description by way of immediate reference, the embodiments - which primarily refer to a system (that is, an apparatus or machine) - are in no way intended to be limited to treating COVID- 19: a variety of other diseases may in fact benefit from treatment via a system according to embodiments.
  • One or more embodiments may rely on the synergistic effect of the combination of different anti-inflammatory agents.
  • hydrogen may play a role as an anti inflammatory molecule itself with the capability of enhancing the efficacy of other anti-inflammatory agents. This may be particularly the case for hydrogen made available to a patient's lungs via an artificial ventilator with a positive pressure, for instance.
  • the effect of the treatment may be appreciably improved as a result of a combination of gases being insufflated at proper temperature, higher than body temperature.
  • one or more embodiments may relate to a system which, in addition to a conventional use in a hospital or a clinic, can be possibly configured for home use and even a portable (wearable) equipment.
  • One or more embodiments may benefit from the possibility of facilitating the addition of antimicrobial or antiviral agents, like ozone or chlorine-releasing molecules.
  • Figure 1 the annexed drawing is a block diagram exemplary of a possible architecture of a system (that is an apparatus or "machine") 100 configures to treat (at least) one patient P affected by a disease such as COVID-19.
  • a disease such as COVID-19.
  • COVID-19 is referred to throughout this description by way of immediate reference, a system such as 100 can be used to treat a variety of other similar diseases.
  • the system 100 may be configured to co-operate with an artificial ventilator PV to which the patient is coupled (in any manner known to those of skill in the art, for instance via tracheotomy cannulae or a respiratory mask).
  • an artificial ventilator PV to which the patient is coupled (in any manner known to those of skill in the art, for instance via tracheotomy cannulae or a respiratory mask).
  • ventilator PV may be a distinct element from the embodiments. It will be similarly appreciated that the system
  • 100 can be comprised of a plurality of elements (components or devices) which - taken individually and per se - are known to those of skill in the art, which makes it unnecessary to provide a more detailed description or each and every one of those elements, components or devices.
  • a system 100 may be configured to be supplied at an input 1 with water W (compatible with clinical use) as resulting from reverse osmosis treatment and addition of an electrolyte to be collected in a water reservoir (tank) 2.
  • water W compatible with clinical use
  • electrolyte to be collected in a water reservoir (tank) 2.
  • reference 3 denotes a direct current (DC) generator coupled to an electrolyzer E where electricity from the generator 3 is used to split water W into oxygen and hydrogen using electrolysis.
  • DC direct current
  • electrolyzers can be manufactured also as small, appliance-size equipment. Like fuel cells, electrolyzers comprises an anode and a cathode separated by an electrolyte.
  • an electrolyzer such as E will generally include an oxygen generator and pipeline 4 and an hydrogen generator and pipeline 5.
  • the oxygen an hydrogen pipelines come down to a hydrogen/oxygen mixer and regulator 6 and the oxygen/hydrogen mixture formed therein is supplied to a nebulizer/aerosol generator 7.
  • the nebulizer/aerosol generator 7 may have a first input port 8 (a pump, for instance) configured to supply into the nebulizer/aerosol generator 7 a metered amount of an anti-inflammatory agent AI.
  • the nebulizer/aerosol generator 7 may have a second input port 9 (again, a pump, for instance) configured to supply into the nebulizer/aerosol generator 7 a metered amount of ozone (or trioxygen) 03, from an ozone generator of any known type in the art (not visible in the Figure for simplicity).
  • a second input port 9 (again, a pump, for instance) configured to supply into the nebulizer/aerosol generator 7 a metered amount of ozone (or trioxygen) 03, from an ozone generator of any known type in the art (not visible in the Figure for simplicity).
  • the nebulizer/aerosol generator 7 may have a third input port 10 (once more a pump, for instance) configured to supply into the nebulizer/aerosol generator 7 a metered amount of a chlorine release agent CR so that the gas-liquid mixture from the generator 7 can be additioned with a chlorine-releasing substance.
  • a third input port 10 once more a pump, for instance
  • the gas-liquid mixture generator 7 can be configured to addition a chlorine releasing substance to the gas-liquid mixture by producing hypochlorous acid via electrolysis of a salt water solution, possibly producing a hypochlorous vapor.
  • the nebulizer/aerosol generator 7 may have an output port coupled to a heater 11 so that the gas- liquid mixture (in practice a mist) formed at 7 and additioned at the nebulizer/aerosol generator 7 with an anti-inflammatory agent AI, and, optionally, ozone 03 and/or chlorine from the agent CR can be controllably heated and supplied to the patient P, for instance via cannulae 12 to the patient ventilator PV.
  • AI anti-inflammatory agent
  • ozone 03 and/or chlorine from the agent CR can be controllably heated and supplied to the patient P, for instance via cannulae 12 to the patient ventilator PV.
  • a system or equipment 100 as exemplified herein can be used in connection with a respiratory machine for treatment of COVID-19 or other diseases leading to severe lung inflammation.
  • Operation of such a system 100 can be controlled via a control unit CU (such as an industrial PC) as a function of signals sensed over the various parts of the system by sensors collectively indicated S and applying corresponding actuation signals to parts of the system (such as the electrolyze E, the mixer 6, the nebulizer/aerosol generator 7 and the pumps associated therewith t, the heater 11) by actuators collectively indicated A.
  • a control unit CU such as an industrial PC
  • sensors collectively indicated S and applying corresponding actuation signals to parts of the system (such as the electrolyze E, the mixer 6, the nebulizer/aerosol generator 7 and the pumps associated therewith t, the heater 11) by actuators collectively indicated A.
  • the conception, design and programming of such a control system (control unit CU, sensors S, actuators A) based on the information provided herein is a task falling within the conventional ability of a designer of control apparatus for medical equipment (heart-lung machines for instance).
  • a system 100 as exemplified herein may involve a hydrogen generator (the electrolyzer E, for instance) based on the well-known principle of electrolysis of water, supplied from a tank 2 containing (pure) water W, either distilled or purified by reverse osmosis, possibly added with an electrolyte like an alkaline metal hydroxide.
  • the electrolyzer E for instance
  • the electrolyzer E based on the well-known principle of electrolysis of water, supplied from a tank 2 containing (pure) water W, either distilled or purified by reverse osmosis, possibly added with an electrolyte like an alkaline metal hydroxide.
  • a gas- liquid mixture generator can be provided (as exemplified at 7 herein) where a flow of gas through a liquid can generate an aerosol containing droplets of adequate dimension.
  • the liquid in question can comprise (pure) water having dissolved or dispersed therein anti-inflammatory agent AI like a corticosteroid drug or non-corticosteroid drug or a natural anti-inflammatory substance.
  • anti-inflammatory agent AI like a corticosteroid drug or non-corticosteroid drug or a natural anti-inflammatory substance.
  • the mixture thus generated can be supplied to a patient P via a ventilator PV or possibly directly insufflated into the respiratory system of the patient P with a positive pressure.
  • the mixture can be heated to a temperature above body temperature via a heater, as exemplified at 11, for instance.
  • the gas supplied to the mixture generator may include hydrogen or a hydrogen-oxygen mixture, which, following mixture generation, can be heated, as exemplified at 11, via a heat exchanger, for instance, which facilitates supply to the patient P (via the ventilator PV, for instance) with a precise control of the temperature (thanks to the control unit CU, for instance.
  • hydrogen and oxygen as produced by a water electrolyzer such as E can be kept separate and mixed together at a mixer 6 comprising a regulation valve (not visible in the figures for reasons of scale) which can be controllably adjusted in order to define the relative oxygen/hydrogen proportions before the mixture is supplied to the mixture generator 7.
  • a regulation valve not visible in the figures for reasons of scale
  • the gas generated at E can be enriched with ozone 03 before being supplied, again with a valve/pump such as 9 controllably adjustable to regulate the relative contents in the resulting mixture before this is supplied to the patient P.
  • the gas generated at E can be enriched with (a vapor of) chlorine releasing substance CR, like hypochlorous acid or one of the chloramines, again with a valve/pump such as 10 controllably adjustable to regulate the relative contents in the resulting mixture before this is supplied to the patient P.
  • a valve/pump such as 10 controllably adjustable to regulate the relative contents in the resulting mixture before this is supplied to the patient P.
  • a lung disease treatment system that is an apparatus, machine or equipment such as 100, for instance
  • a gas-liquid mixture generator for instance, 7 configured to receive (for instance, 6) hydrogen from said electrolytic generator and produce therefrom a gas-liquid mixture containing an anti-inflammatory agent (for instance, AI), an insufflation line (for instance, 11, 12) coupled to the gas-liquid mixture generator and configured to insufflate said gas-liquid mixture containing an anti-inflammatory agent towards the respiratory system of a patient (for instance, P).
  • an anti-inflammatory agent for instance, AI
  • an insufflation line for instance, 11, 12
  • said insufflation line may comprises a heater (for instance, 11) configured to heat said gas-liquid mixture insufflated towards the respiratory system of a patient.
  • said heater may be configured to heat said gas-liquid mixture insufflated towards the respiratory system of a patient to a temperature higher than the patient body temperature .
  • said insufflation line may comprises at least one cannula
  • said electrolytic hydrogen generator may configured to generate via electrolysis both hydrogen (for instance, 5) and oxygen (for instance, 4), said gas-liquid mixture generator may be configured to receive from said electrolytic generator both hydrogen and oxygen, wherein said gas-liquid mixture contains both hydrogen and oxygen.
  • said electrolytic hydrogen generator may have separate output lines for hydrogen and oxygen
  • a mixer for instance, 6
  • said mixer configured to supply said gas-liquid mixture generator with a proportioned mixture of hydrogen and oxygen (that is a mixture containing - possibly adjustable - a relative proportion of hydrogen and oxygen).
  • said electrolytic hydrogen generator may contain a filling of water (for instance, W) additioned with an electrolyte .
  • said filling of water may comprise distilled water or water purified by reverse osmosis.
  • said electrolyte may comprise an alkaline metal hydroxide.
  • said gas-liquid mixture generator may be configured to produce a gas- liquid mixture containing an anti-inflammatory agent selected from of corticosteroid drugs, non corticosteroid drugs or natural anti-inflammatory substances .
  • Exemplary corticosteroid drugs may include cortisone, prednisolone, dexamethasone, fluticasone propionate (as used for asthma and chronic allergy).
  • Exemplary non-corticosteroid drugs may include ketoprofene, indomethacin, coxibi.
  • Natural anti-inflammatory substances may include salicylic acid-based substances and harpagosides.
  • said gas-liquid mixture generator may be configured (for instance, at 9) to addition ozone (for instance, 03) to said gas- liquid mixture.
  • said gas-liquid mixture generator may be configured (for instance, at 10) to addition a chlorine-releasing substance to said gas-liquid mixture.
  • said chlorine- releasing substance may be selected from hypochlorous acid and chloramines.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Materials Engineering (AREA)
  • Metallurgy (AREA)
  • Electrochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Automation & Control Theory (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A system (100) for treating lung diseases such as COVID-19 comprises: an electrolytic hydrogen generator (E), a gas-liquid mixture generator (7) configured to receive (6) hydrogen from the electrolytic generator (E) and produce (8) therefrom a gas-liquid mixture containing an anti-inflammatory agent (AI), an insufflation line (11, 12) coupled to the gas-liquid mixture generator (7) and configured to insufflate the gas-liquid mixture containing an anti-inflammatory agent (AI) towards the respiratory system of a patient (P).

Description

"Treatment of lung diseases" kkkk
Technical field
The present disclosure relates to treating lung diseases such as lung (respiratory) inflammation diseases.
Coronavirus disease 2019 (briefly COVID-19), an infection disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is exemplary of such a disease.
Technological background
Diseases such as COVID-19 are primarily spread between people during close contact and may lead to symptoms such as fever, cough, shortness of breath, loss of smell and fatigue.
Pneumonia and acute respiratory distress are possible complications which may result in death of the person infected.
At least at the time the instant application is filed, no vaccine or specific antiviral treatment is known and treatment is mostly symptomatic and supportive.
The disease has been countered mostly via preventive measures such as repeated accurate hand washing, wearing protective face masks, social distancing, (self)isolation of "positive" subjects and/or subjects suspected to be infected.
This has resulted in massive travel restrictions, lockdowns, extensive testing and facility closures, with a tremendous effect on economy expected to be prolonged in the years to come. Object and summary
The object of one or more embodiments is to provide a solution that will be able to contribute in countering diseases such as COVID-19 by providing an effective treatment of such devices.
According to one or more embodiments, the above object may be achieved thanks to a system having the characteristics set for in the claims that follow.
The claims form an integral part of the technical teachings provided herein in relation to the embodiments .
One or more embodiments may facilitate treatment of severe diseases caused by infections such as COV1D- 19 infection, dealing directly the inflammation in the lungs which can trigger severe consequences potentially leading to death.
It will be otherwise appreciated that while COVID- 19 is referred to throughout this description by way of immediate reference, the embodiments - which primarily refer to a system (that is, an apparatus or machine) - are in no way intended to be limited to treating COVID- 19: a variety of other diseases may in fact benefit from treatment via a system according to embodiments.
One or more embodiments may rely on the synergistic effect of the combination of different anti-inflammatory agents.
For instance, hydrogen may play a role as an anti inflammatory molecule itself with the capability of enhancing the efficacy of other anti-inflammatory agents. This may be particularly the case for hydrogen made available to a patient's lungs via an artificial ventilator with a positive pressure, for instance.
Also, it was found that the effect of the treatment may be appreciably improved as a result of a combination of gases being insufflated at proper temperature, higher than body temperature.
For instance, one or more embodiments may relate to a system which, in addition to a conventional use in a hospital or a clinic, can be possibly configured for home use and even a portable (wearable) equipment.
One or more embodiments may benefit from the possibility of facilitating the addition of antimicrobial or antiviral agents, like ozone or chlorine-releasing molecules.
Brief description of the drawings
One or more embodiments will now be described, purely by way of non-limiting example, with reference to the annexed drawing, which includes a single figure, designated Figure 1, in the form a block diagram exemplary of a possible architecture of a system according to embodiments as per the present description.
Detailed description of examples of embodiments
In the ensuing description, various specific details are illustrated in order to provide an in-depth understanding of various examples of embodiments according to the description. The embodiments may be obtained without one or more of the specific details, or with other methods, components, materials, etc. In other cases, known structures, materials, or operations are not illustrated or described in detail so that the various aspects of the embodiments will not be obscured.
Reference to "an embodiment" or "one embodiment" in the framework of the present description is intended to indicate that a particular configuration, structure, or characteristic described in relation to the embodiment is comprised in at least one embodiment. Consequently, phrases such as "in an embodiment" or "in one embodiment" that may be present in various points of the present description do not necessarily refer exactly to one and the same embodiment. Moreover, particular conformations, structures, or characteristics may be combined in any adequate way in one or more embodiments.
The headings/references used herein are provided merely for convenience and hence do not define the sphere of protection or the scope of the embodiments.
Figure 1 the annexed drawing is a block diagram exemplary of a possible architecture of a system (that is an apparatus or "machine") 100 configures to treat (at least) one patient P affected by a disease such as COVID-19.
As discussed, while COVID-19 is referred to throughout this description by way of immediate reference, a system such as 100 can be used to treat a variety of other similar diseases.
As exemplified herein, the system 100 may be configured to co-operate with an artificial ventilator PV to which the patient is coupled (in any manner known to those of skill in the art, for instance via tracheotomy cannulae or a respiratory mask).
Also, it will be appreciated that the ventilator PV may be a distinct element from the embodiments. It will be similarly appreciated that the system
100 can be comprised of a plurality of elements (components or devices) which - taken individually and per se - are known to those of skill in the art, which makes it unnecessary to provide a more detailed description or each and every one of those elements, components or devices.
In one or more embodiments as exemplified in the Figure, a system 100 may be configured to be supplied at an input 1 with water W (compatible with clinical use) as resulting from reverse osmosis treatment and addition of an electrolyte to be collected in a water reservoir (tank) 2.
In the Figure, reference 3 denotes a direct current (DC) generator coupled to an electrolyzer E where electricity from the generator 3 is used to split water W into oxygen and hydrogen using electrolysis.
As known to those of skill in the art, electrolyzers can be manufactured also as small, appliance-size equipment. Like fuel cells, electrolyzers comprises an anode and a cathode separated by an electrolyte.
While different electrolyzers may function in different ways (as a function of the electrolyte involved, for instance) an electrolyzer such as E will generally include an oxygen generator and pipeline 4 and an hydrogen generator and pipeline 5.
In one or more embodiments as exemplified in the Figure, the oxygen an hydrogen pipelines come down to a hydrogen/oxygen mixer and regulator 6 and the oxygen/hydrogen mixture formed therein is supplied to a nebulizer/aerosol generator 7.
In one or more embodiments as exemplified in the Figure, the nebulizer/aerosol generator 7 may have a first input port 8 (a pump, for instance) configured to supply into the nebulizer/aerosol generator 7 a metered amount of an anti-inflammatory agent AI.
In one or more embodiments as exemplified in the Figure the nebulizer/aerosol generator 7 may have a second input port 9 (again, a pump, for instance) configured to supply into the nebulizer/aerosol generator 7 a metered amount of ozone (or trioxygen) 03, from an ozone generator of any known type in the art (not visible in the Figure for simplicity).
In one or more embodiments as exemplified in the Figure the nebulizer/aerosol generator 7 may have a third input port 10 (once more a pump, for instance) configured to supply into the nebulizer/aerosol generator 7 a metered amount of a chlorine release agent CR so that the gas-liquid mixture from the generator 7 can be additioned with a chlorine-releasing substance.
In one or more embodiments the gas-liquid mixture generator 7 can be configured to addition a chlorine releasing substance to the gas-liquid mixture by producing hypochlorous acid via electrolysis of a salt water solution, possibly producing a hypochlorous vapor.
In one or more embodiments as exemplified in the Figure the nebulizer/aerosol generator 7 may have an output port coupled to a heater 11 so that the gas- liquid mixture (in practice a mist) formed at 7 and additioned at the nebulizer/aerosol generator 7 with an anti-inflammatory agent AI, and, optionally, ozone 03 and/or chlorine from the agent CR can be controllably heated and supplied to the patient P, for instance via cannulae 12 to the patient ventilator PV.
A system or equipment 100 as exemplified herein can be used in connection with a respiratory machine for treatment of COVID-19 or other diseases leading to severe lung inflammation.
Operation of such a system 100 can be controlled via a control unit CU (such as an industrial PC) as a function of signals sensed over the various parts of the system by sensors collectively indicated S and applying corresponding actuation signals to parts of the system (such as the electrolyze E, the mixer 6, the nebulizer/aerosol generator 7 and the pumps associated therewith t, the heater 11) by actuators collectively indicated A. The conception, design and programming of such a control system (control unit CU, sensors S, actuators A) based on the information provided herein is a task falling within the conventional ability of a designer of control apparatus for medical equipment (heart-lung machines for instance).
A system 100 as exemplified herein may involve a hydrogen generator (the electrolyzer E, for instance) based on the well-known principle of electrolysis of water, supplied from a tank 2 containing (pure) water W, either distilled or purified by reverse osmosis, possibly added with an electrolyte like an alkaline metal hydroxide.
In a system 100 as exemplified herein, a gas- liquid mixture generator can be provided (as exemplified at 7 herein) where a flow of gas through a liquid can generate an aerosol containing droplets of adequate dimension.
As exemplified herein, the liquid in question can comprise (pure) water having dissolved or dispersed therein anti-inflammatory agent AI like a corticosteroid drug or non-corticosteroid drug or a natural anti-inflammatory substance.
As exemplified herein, the mixture thus generated can be supplied to a patient P via a ventilator PV or possibly directly insufflated into the respiratory system of the patient P with a positive pressure.
As exemplified herein, the mixture can be heated to a temperature above body temperature via a heater, as exemplified at 11, for instance.
As exemplified herein, the gas supplied to the mixture generator (as illustrated at 7, for instance) may include hydrogen or a hydrogen-oxygen mixture, which, following mixture generation, can be heated, as exemplified at 11, via a heat exchanger, for instance, which facilitates supply to the patient P (via the ventilator PV, for instance) with a precise control of the temperature (thanks to the control unit CU, for instance.
As exemplified herein, hydrogen and oxygen as produced by a water electrolyzer such as E can be kept separate and mixed together at a mixer 6 comprising a regulation valve (not visible in the figures for reasons of scale) which can be controllably adjusted in order to define the relative oxygen/hydrogen proportions before the mixture is supplied to the mixture generator 7.
As discussed, the gas generated at E can be enriched with ozone 03 before being supplied, again with a valve/pump such as 9 controllably adjustable to regulate the relative contents in the resulting mixture before this is supplied to the patient P.
As discussed, the gas generated at E can be enriched with (a vapor of) chlorine releasing substance CR, like hypochlorous acid or one of the chloramines, again with a valve/pump such as 10 controllably adjustable to regulate the relative contents in the resulting mixture before this is supplied to the patient P.
As exemplified herein, a lung disease treatment system (that is an apparatus, machine or equipment such as 100, for instance) may comprise: an electrolytic hydrogen generator (for instance,
E), a gas-liquid mixture generator (for instance, 7) configured to receive (for instance, 6) hydrogen from said electrolytic generator and produce therefrom a gas-liquid mixture containing an anti-inflammatory agent (for instance, AI), an insufflation line (for instance, 11, 12) coupled to the gas-liquid mixture generator and configured to insufflate said gas-liquid mixture containing an anti-inflammatory agent towards the respiratory system of a patient (for instance, P).
In a system as exemplified herein, said insufflation line may comprises a heater (for instance, 11) configured to heat said gas-liquid mixture insufflated towards the respiratory system of a patient.
In a system as exemplified herein, said heater may be configured to heat said gas-liquid mixture insufflated towards the respiratory system of a patient to a temperature higher than the patient body temperature .
In a system as exemplified herein, said insufflation line may comprises at least one cannula
(for instance, 12) configured for either direct insufflation of said gas-liquid mixture into the respiratory system of a patient or coupling to a patient ventilator (for instance, PV). In a system as exemplified herein: said electrolytic hydrogen generator may configured to generate via electrolysis both hydrogen (for instance, 5) and oxygen (for instance, 4), said gas-liquid mixture generator may be configured to receive from said electrolytic generator both hydrogen and oxygen, wherein said gas-liquid mixture contains both hydrogen and oxygen.
In a system as exemplified herein: said electrolytic hydrogen generator may have separate output lines for hydrogen and oxygen, a mixer (for instance, 6) may be provided intermediate said separate output lines for hydrogen and oxygen and said gas-liquid mixture generator, the mixer configured to supply said gas-liquid mixture generator with a proportioned mixture of hydrogen and oxygen (that is a mixture containing - possibly adjustable - a relative proportion of hydrogen and oxygen).
In a system as exemplified herein, said electrolytic hydrogen generator may contain a filling of water (for instance, W) additioned with an electrolyte .
In a system as exemplified herein, said filling of water may comprise distilled water or water purified by reverse osmosis.
In a system as exemplified herein, said electrolyte may comprise an alkaline metal hydroxide.
In a system as exemplified herein, said gas-liquid mixture generator may be configured to produce a gas- liquid mixture containing an anti-inflammatory agent selected from of corticosteroid drugs, non corticosteroid drugs or natural anti-inflammatory substances .
Exemplary corticosteroid drugs may include cortisone, prednisolone, dexamethasone, fluticasone propionate (as used for asthma and chronic allergy).
Exemplary non-corticosteroid drugs (FANS) may include ketoprofene, indomethacin, coxibi.
Natural anti-inflammatory substances may include salicylic acid-based substances and harpagosides.
In a system as exemplified herein, said gas-liquid mixture generator may be configured (for instance, at 9) to addition ozone (for instance, 03) to said gas- liquid mixture.
In a system as exemplified herein, said gas-liquid mixture generator may be configured (for instance, at 10) to addition a chlorine-releasing substance to said gas-liquid mixture.
In a system as exemplified herein, said chlorine- releasing substance may be selected from hypochlorous acid and chloramines.
Without prejudice to the underlying principles, the details of construction and the embodiments may vary, even significantly, with respect to what has been illustrated herein purely by way of non-limiting example.
The extent of protection is determined by the annexed claims.

Claims

1. A lung disease treatment system (100), comprising : an electrolytic hydrogen generator (E), a gas-liquid mixture generator (7) configured to receive (6) hydrogen from said electrolytic generator (E) and produce (8) therefrom a gas-liquid mixture containing an anti-inflammatory agent (AI), an insufflation line (11, 12) coupled to the gas- liquid mixture generator (7) and configured to insufflate said gas-liquid mixture containing an anti inflammatory agent (AI) towards the respiratory system of a patient (P).
2. The system (100) of claim 1, wherein said insufflation line (11, 12) comprises a heater (11) configured to heat said gas-liquid mixture insufflated towards the respiratory system of a patient (P).
3. The system (100) of claim 2, wherein said heater (11) is configured to heat said gas-liquid mixture insufflated towards the respiratory system of a patient (P) to a temperature higher than the patient body temperature.
4. The system (100) of any of the previous claims, wherein said insufflation line (11, 12) comprises at least one cannula (12) configured for either direct insufflation of said gas-liquid mixture into the respiratory system of a patient (P) or coupling to a patient ventilator (PV).
5. The system (100) of any of the previous claims, wherein: said electrolytic hydrogen generator (E) is configured to generate via electrolysis both hydrogen (5) and oxygen (4),said gas-liquid mixture generator (7) is configured (6) to receive from said electrolytic generator (E) both hydrogen (5) and oxygen (4) wherein said gas-liquid mixture contains both hydrogen (5) and oxygen (4).
6. The system (100) of claim 5, wherein: said electrolytic hydrogen generator (E) has separate output lines for hydrogen (5) and oxygen (4), a mixer (6) is provided intermediate said separate output lines for hydrogen (5) and oxygen (4) and said gas-liquid mixture generator (7), the mixer configured (6) to supply said gas-liquid mixture generator (7) with a proportioned mixture of hydrogen and oxygen.
7 . The system (100) of any of the previous claims, wherein said electrolytic hydrogen generator (E) contains a filling of water (W) additioned with an electrolyte.
8. The system (100) of any of the previous claims, wherein said filling of water (W) comprises distilled water or water purified by reverse osmosis.
9. The system (100) of claim 7 or claim 8, wherein said electrolyte comprises an alkaline metal hydroxide.
10 . The system (100) of any of the previous claims, wherein said gas-liquid mixture generator (7) is configured to produce (8) a gas-liquid mixture containing an anti-inflammatory agent (AI) selected from of corticosteroid drugs, non-corticosteroid drugs or natural anti-inflammatory substances.
11. The system (100) of any of the previous claims, wherein said gas-liquid mixture generator (7) is configured (9) to addition ozone (03) to said gas- liquid mixture.
12. The system (100) of any of the previous claims, wherein said gas-liquid mixture generator (7) is configured (9) to addition ozone (03) to said gas- liquid mixture.
13. The system (100) of any of the previous claims, wherein said gas-liquid mixture generator (7) is configured (10) to addition a chlorine-releasing substance to said gas-liquid mixture.
14. The system (100) of claim 13, wherein said chlorine-releasing substance is selected from hypochlorous acid and chloramines.
15. The system (100) of any of the previous claims, configured as a home appliance and/or as a portable/wearable equipment
PCT/IB2020/054826 2020-05-21 2020-05-21 Treatment of lung diseases Ceased WO2021234435A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/IB2020/054826 WO2021234435A1 (en) 2020-05-21 2020-05-21 Treatment of lung diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2020/054826 WO2021234435A1 (en) 2020-05-21 2020-05-21 Treatment of lung diseases

Publications (1)

Publication Number Publication Date
WO2021234435A1 true WO2021234435A1 (en) 2021-11-25

Family

ID=70804863

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2020/054826 Ceased WO2021234435A1 (en) 2020-05-21 2020-05-21 Treatment of lung diseases

Country Status (1)

Country Link
WO (1) WO2021234435A1 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010132360A1 (en) * 2009-05-11 2010-11-18 Oculus Innovative Sciences, Inc. Methods of treating or preventing influenza associated illness with oxidative reductive potential water solutions
US20150190604A1 (en) * 2014-01-07 2015-07-09 Hsin-Yung Lin Gas generating system for health use
US20150359979A1 (en) * 2014-06-11 2015-12-17 Nihon Kohden Corporation Hydrogen molecule therapy apparatus and hydrogen molecule therapy method
WO2017149684A1 (en) * 2016-03-01 2017-09-08 株式会社グレイトチレン Wet high-concentration hydrogen-mixed-gas respiration system
US20180028774A1 (en) * 2016-07-27 2018-02-01 Hsin-Yung Lin Healthy gas generating system
US20190186028A1 (en) * 2013-06-19 2019-06-20 Hsin-Yung Lin Anti-explosion gas generator for health use

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010132360A1 (en) * 2009-05-11 2010-11-18 Oculus Innovative Sciences, Inc. Methods of treating or preventing influenza associated illness with oxidative reductive potential water solutions
US20190186028A1 (en) * 2013-06-19 2019-06-20 Hsin-Yung Lin Anti-explosion gas generator for health use
US20150190604A1 (en) * 2014-01-07 2015-07-09 Hsin-Yung Lin Gas generating system for health use
US20150359979A1 (en) * 2014-06-11 2015-12-17 Nihon Kohden Corporation Hydrogen molecule therapy apparatus and hydrogen molecule therapy method
WO2017149684A1 (en) * 2016-03-01 2017-09-08 株式会社グレイトチレン Wet high-concentration hydrogen-mixed-gas respiration system
US20180028774A1 (en) * 2016-07-27 2018-02-01 Hsin-Yung Lin Healthy gas generating system

Similar Documents

Publication Publication Date Title
US10010694B2 (en) Gas generating system for health use
US11865265B2 (en) Anti-explosion gas generator for health use
Kondrashove et al. The primary physico-chemical mechanism for the beneficial biological/medical effects of negative air ions
JP3193762U (en) Explosion-proof gas generator for health use
US20080087283A1 (en) Apparatus for and related method of inhibiting lewis acid degradation in a vaporizer
JP6976291B2 (en) Gas generator
US9463157B2 (en) Inhalation-type pharmaceutical composition for the treatment of Alzheimer's disease and preparation method thereof
CN102481357A (en) Methods of treating or preventing influenza associated illness with oxidative reductive potential water solutions
KR20150120856A (en) Inhalation-type pharmaceutical composition for the treatment of lung cancer and preparation method thereof
US9381152B2 (en) Inhalation-type pharmaceutical composition for the treatment of Parkinson's disease and preparation method thereof
WO2021234435A1 (en) Treatment of lung diseases
US20150272870A1 (en) Inhalation-type pharmaceutical composition for the treatment of gout and preparation method thereof
US20230390153A1 (en) Hydrogen generatiion and delivery device and methods
US9827193B2 (en) Inhalation-type pharmaceutical composition for the treatment of hypertension and preparation method thereof
DE102015104361B4 (en) PHARMACEUTICAL COMPOSITION OF THE INHALATION TYPE FOR TREATMENT OF ROLLING IGNITION AND PREPARATION METHOD THEREFOR
Chawla et al. Guidelines for noninvasive ventilation in acute respiratory failure.
TWI830997B (en) Ventilator system
WO2025214225A1 (en) Pharmaceutical chlorine dioxide antimicrobial liquid agent, preparation method therefor, and use thereof
CN107583156A (en) A kind of type of respiration Anesthesia machine
CN219430135U (en) Mixed gas generating device capable of being externally connected with breathing tube and mixed gas generating system
DE102015104315A1 (en) Pharmaceutical composition for inhalation for the treatment of diabetes and process for the preparation thereof
Case Trichlorethanol: Animal Experimentation.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20727858

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20727858

Country of ref document: EP

Kind code of ref document: A1